Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2025)

Crinetics Pharmaceuticals (CRNX) has 4 years of Current Deferred Revenue data on record, last reported at $1.2 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 43.24% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 43.24%, while the annual FY2025 figure was $1.2 million, 43.24% down from the prior year.
  • Current Deferred Revenue reached $1.2 million in Q4 2025 per CRNX's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.4 million in Q2 2022 and bottomed at $1.2 million in Q4 2025.
  • Average Current Deferred Revenue over 4 years is $4.2 million, with a median of $2.4 million recorded in 2022.
  • The widest YoY moves for Current Deferred Revenue: up 193.36% in 2023, down 75.35% in 2023.
  • A 4-year view of Current Deferred Revenue shows it stood at $8.3 million in 2022, then crashed by 75.35% to $2.1 million in 2023, then grew by 5.84% to $2.2 million in 2024, then crashed by 43.24% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $1.2 million in Q4 2025, $1.6 million in Q3 2025, and $1.9 million in Q2 2025.